Cribstone Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Cribstone Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-191	Closed	-$3K	–	480
2019 Q3	$3K	Hold	191	–	–	﹤0.01%	511
2019 Q2	$3K	Hold	191	–	–	﹤0.01%	560
2019 Q1	$3K	Hold	191	–	–	﹤0.01%	595
2018 Q4	$3K	Hold	191	–	–	﹤0.01%	633
2018 Q3	$5K	Hold	191	–	–	﹤0.01%	617
2018 Q2	$5K	Hold	191	–	–	﹤0.01%	622
2018 Q1	$4K	Buy	191 +36	+23%	+$885	﹤0.01%	642
2017 Q4	$3K	Hold	155	–	–	﹤0.01%	747
2017 Q3	$4K	Hold	155	–	–	﹤0.01%	623
2017 Q2	$2K	Hold	155	–	–	﹤0.01%	670
2017 Q1	$2K	Buy	+155	New	+$2.08K	﹤0.01%	694

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cribstone Capital Management's NTLA Position: Q4 2019 in Review

Cribstone Capital Management sold out of Intellia Therapeutics (NTLA) in Q4 2019, closing a stake of 191 shares — an estimated $3K sold.

Cribstone Capital Management first reported a position in NTLA in Q1 2017 and held it in 11 quarters. The position peaked at $5K in Q3 2018. 143 funds tracked by Wall St. Rank hold NTLA as of Q4 2019.

Cribstone Capital Management reported no remaining Intellia Therapeutics position as of Q4 2019 after selling out during the quarter.
Cribstone Capital Management sold 191 Intellia Therapeutics shares in Q4 2019, an estimated $3K.
Cribstone Capital Management first reported a position in Intellia Therapeutics in Q1 2017 and held it in 11 quarters.
Cribstone Capital Management's Intellia Therapeutics position peaked at $5K in Q3 2018.
143 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2019.

Based on Cribstone Capital Management's 13F filing for Q4 2019, filed 8 Jan 2020.